Monitoring neuropeptide-specific proteases: Processing of the proopiomelanocortin peptides adrenocorticotropin and α-melanocyte-stimulating hormone in the skin

Experimental Dermatology

Volumn 15, Issue 10, 2006, Pages 751-761

  König, Simone ^a   Luger, Thomas A ^a   Scholzen, Thomas E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adrenocorticotropin; Angiotensin converting enzyme; Mass spectrometry; Melanocyte stimulating hormone; Neprilysin

Indexed keywords

ALPHA INTERMEDIN; COMPLEMENTARY DNA; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE; MELANOCORTIN RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; NEUROPEPTIDE; OMAPATRILAT; PEPTIDASE; PROOPIOMELANOCORTIN; PROTEINASE;

ANALYTIC METHOD; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; EXTRACELLULAR SPACE; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTEIN SYNTHESIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RADIORECEPTOR ASSAY; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SKIN INFLAMMATION; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ADRENOCORTICOTROPIC HORMONE; ALPHA-MSH; ENZYME ACTIVATION; HUMANS; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PRO-OPIOMELANOCORTIN; RECEPTORS, MELANOCORTIN; SKIN; SUBSTRATE SPECIFICITY;

EID: 33748892811     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2006.00472.x     Document Type: Review

References (98)

1. Castro M G, Morrison E. Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit Rev Neurobiol 1997: 11: 35-57.
2. Benjannet S, Rondeau N, Day R, Chretien M, Seidah N G. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A 1991: 88: 3564-3568.
3. White A, Gibson S. ACTH precursors: Biological significance and clinical relevance. Clin Endocrinol (Oxf) 1998: 48: 251-255.
4. Scholzen T E, König S, Fastrich M, Böhm M, Luger T A. Processing of POMC peptides by dermal microvascular endothelial cells: implication for EC biological function and skin inflammation. Exp Dermatol 2004: 13: 587-588.
5. Koenig S, Fastrich M, Luger T A, Scholzen T E. Monitoring membrane action: Processing of POMC peptides by dermal microvascular endothelial cells. In: 52nd ASMS Conference: 2004, Nashville, TN, USA, 2004.
6. Scholzen T E, König S, Fastrich M, Böhm M, Brzoska T, Luger T A. Regulation of proopiomelanocortin peptide-induced melanocortin 1 receptor signaling by proteolytic peptidases in dermal microvascular endothelial cells. J Invest Dermatol 2005: 125: 273 (A47).
7. Isaac R E, Siviter R J, Stancombe P, Coates D, Shirras A D. Conserved roles for peptidases in the processing of invertebrate neuropeptides. Biochem Soc Trans 2000: 28: 460-464.
8. Luger T A, Scholzen T, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 2003: 994: 133-140.
9. Slominski A, Wortsman J, Luger T A, Paus R, Solomon S G. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000: 80: 979-1020.
10. Catania A, Gatti S, Colombo G, Lipton J M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004: 56: 1-29.
11. Scholzen T E, Armstrong C A, Bunnett N W, Luger T A, Olerud J E, Ansel J C. Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998: 7: 81-96.
12. Peters E M, Ericson M, Hosoi J et al. Neuropeptide control mechanisms in cutaneous biology: Physiological and clinical significance. J Invest Dermatol 2006: 126, in press.
13. Arends R J, Rotllant J, Metz J R, Mancera J M, Wendelaar Bonga S E, Flik G. α-MSH acetylation in the pituitary gland of the sea bream (Sparus aurata L.) in response to different backgrounds, confinement and air exposure. J Endocrinol 2000: 166: 427-435.
14. Tsatmalia M, Wakamatsu K, Graham A J, Thody A J. Skin POMC peptides: their binding affinities and activation of the human MC1 receptor. Ann N Y Acad Sci 1999: 885: 466-469.
15. Wakamatsu K, Graham A, Cook D, Thody A J. Characterization of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res 1997: 10: 288-297.
16. Slominski A, Roloff B, Curry J, Dahiya M, Szczesniewski A, Wortsman J. The skin produces urocortin. J Clin Endocrinol Metab 2000: 85: 815-823.
17. Peters E M, Tobin D J, Seidah N G, Schallreuter K U. Pro-opiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. J Invest Dermatol 2000: 114: 430-437.
18. Schiller M, Kubitschek U, Scholzen T et al. Human dermal fibroblasts express prohormone convertases 1 and 2 and produce proopiomelanocortin-derived peptides. J Invest Dermatol 2001: 117: 227-235.
19. Scholzen T, Kalden D-H, Brzoska T et al. Expression of proopiomelanocortin peptides in human dermal microvascular endothelial cells: Evidence for a regulation by ultraviolet light and interleukin-1. J Invest Dermatol 2000: 115: 1021-1028.
20. Hartmeyer M, Scholzen T, Becher E, Bhardwaj R S, Schwarz T, Luger T A. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol 1997: 159: 1930-1937.
21. Slominski A. Identification of beta-endorphin, alpha-MSH and ACTH peptides in cultured human melanocytes, melanoma and squamous cell carcinoma cells by RP-HPLC. Exp Dermatol 1998: 7: 213.
22. Slominski A, Heasley D, Mazurkiewicz J E, Ermak G, Baker J, Carlson J A. Expression of proopiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides in skin of basal cell carcinoma patients. Hum Pathol 1999: 30: 208-215.
23. Lansac G, Dong W, Dubois C M et al. Lipopolysaccharide mediated regulation of neuroendocrine associated proprotein convertases and neuropeptide precursor processing in the rat spleen. J Neuroimmunol 2006: 171: 57-71.
24. Slominski A, Zbytek B, Zmijewski M et al. Corticotropin releasing hormone and the skin. Front Biosci 2006: 11: 2230.
25. Slominski A, Plonka P M, Pisarchik A et al. Preservation of eumelanin hair pigmentation in proopiomelanocortin-deficient mice on a nonagouti (a/a) genetic background. Endocrinology 2005: 146: 1245.
26. Assie G, Bahurel H, Bertherat J, Kujas M, Legmann P, Bertagna X. The Nelson's syndrome revisited. Pituitary 2004: 7: 209-215.
27. Raffin-Sanson M L, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: From physiology to pathological conditions. Eur J Endocrinol 2003: 149: 79-90.
28. Cone R D. Anatomy and regulation of the central melanocortin system. Nat Neurosci 2005: 8: 571-578.
29. Pritchard L E, Turnbull A V, White A. Pro-opiomelanocortin processing in the hypothalamus: Impact on melanocortin signaling and obesity. J Endocrinol 2002: 172: 411-421.
30. Slominski A, Tobin D J, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004: 84: 1155-1228.
31. Böhm M, Raghunath M, Sunderkötter C et al. Collagen metabolism is a novel target of the neuropeptide alpha melanocyte stimulating hormone. J Biol Chem 2004: 279: 6959-6966.
32. Zouboulis C C, Böhm M. Neuroendocrine regulation of sebocytes - a pathogenic link between stress and acne. Exp Dermatol 2004: 13: 31-35.
33. Tsatmali M, Ancans J, Yukitake J, Thody A J. Skin POMC peptides: Their actions at the human MC-1 receptor and roles in the tanning response. Pigment Cell Res 2000: 13 (Suppl. 8): 125.
34. Spencer J D, Chavan B, Marles L K, Kauser S, Rokos H, Schallreuter K U. A novel mechanism in control of human pigmentation by {beta}-melanocyte-stimulating hormone and 7-tetrahydrobiopterin. J Endocrinol 2005: 187: 293.
35. Smith E M, Hughes T K Jr, Hashemi F, Stefano G B. Immunosuppressive effects of corticotropin and melanotropin and their possible significance in human immunodeficiency virus infection. Proc Natl Acad Sci U S A 1992: 89: 782-786.
36. Duvaux-Miret O, Stefano G B, Smith E M, Dissous C, Capron A. Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoactive neuropeptides. Proc Natl Acad Sci U S A 1992: 89: 778-781.
37. Verma P S, Miller R L, Taylor R E, O'Donohue T L, Adams R G. Inhibition of canine lung angiotensin converting enzyme by ACTH and structurally related peptides. Biochem Biophys Res Commun 1982: 104: 1484-1488.
38. Deschodt-Lanckman M, Vanneste Y, Loir B et al. Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture. Int J Cancer 1990: 46: 1124-1130.
39. Salzet M, Salzet-Raveillon B, Cocquerelle C et al. Leech immunocytes contain proopiomelanocortin: Nitric oxide mediates hemolymph proopiomelanocortin processing. J Immunol 1997: 159: 5400-5411.
40. Ganong W F. Blood, pituitary, and brain renin-angiotensin systems and regulation of secretion of anterior pituitary gland. Front Neuroendocrinol 1993: 14: 233-249.
41. Ritchie J C, Davis T P, Nemeroff C B. Action of three ectopeptidases on corticotropin-releasing factor: Metabolism and functional aspects. Neuropsychopharmacology 2003: 28: 22-33.
42. Wang X C, Burbach J P H, Verhoef C J, De Wied D. Proteolysis of adrenocorticotropin in brain. Characterization of cleavage sites by peptidases in synaptic membranes and formation of peptide fragments. J Biol Chem 1983: 258: 7942-7947.
43. Potaman V N, Alfeeva L Y, Kamensky A A, Nezavibatko V N. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: An inhibitor study. Peptides 1993: 14: 491-495.
44. Rossi G P. Dual ACE and NEP inhibitors: A review of the pharmacological properties of MDL 100,240. Cardiovasc Drug Rev 2003: 21: 51-66.
45. Skidgel R A, Erdos E G. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: A brief history, the beginning and follow-ups to early studies. Peptides 2004: 25: 521-525.
46. Kubota E, Dean R G, Balding L C, Burrell L M. Inhibition of peptidases in the control of blood pressure. Essays Biochem 2002: 38: 129-139.
47. Stryer L. Biochemistry. New York: W. H. Freeman & Co., 1995.
48. Worthley M I, Corti R, Worthley S G. Vasopeptidase inhibitors: Will they have a role in clinical practice? Br J Clin Pharmacol 2004: 57: 27-36.
49. Quaschning T, Galle J, Wanner C. Vasopeptidase inhibition: A new treatment approach for endothelial dysfunction. Kidney Int 2003: 84: S54-S57.
50. Fink C A. Dual inhibitors of angiotensin converting enzyme and neutral endopeptidase. ACE Inhibitors 2001: 155-162.
51. Ferrario C M, Trask A J, Jessup J A. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005: 289: H2281-H2290.
52. Barnes K, Turner A J. The endothelin system and endothelin-converting enzyme in the brain: Molecular and cellular studies. Neurochem Res 1997: 22: 1033-1040.
53. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993: 268: 9496-9503.
54. Perich R B, Jackson B, Johnston C I. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol 1994: 266: 201-211.
55. Strittmatter S M, Thiele E A, Kapiloff M S, Snyder S H. A rat brain isozyme of angiotensin-converting enzyme. Unique specificity for amidated peptide substrates. J Biol Chem 1985: 260: 9825-9832.
56. Roques B P, Noble F, Dauge V, Fournie-Zaluski M C, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993: 45: 87-146.
57. Ruschitzka F, Corti R, Quaschning T, Hermann M, Luscher T F. Vasopeptidase inhibitors - concepts and evidence. Nephrol Dial Transplant 2001: 16: 1532-1535.
58. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: Novel therapy for patients with cardiovascular disorders. Drugs 2003: 63: 2185-2202.
59. Flordellis C S, Goumenos D, Kourounis G, Tsementzis S A, Paris H, Vlachojiannis J. The shift in the "paradigm"of the pharmacology of hypertension. Curr Top Med Chem 2004: 4: 487-498.
60. Campbell D J. Vasopeptidase inhibition. Hypertension 2003: 41: 383-389.
61. Turner A J. Cell-surface peptidases in health and disease: Old enzymes and new developments. Int Congr Ser 2001: 1218: 17-27.
62. Li C, Hersh L B. Neprilysin: Assay methods, purification, and characterization. Methods Enzymol 1995: 248: 253-263.
63. Riemann D, Bloß T, Wulfänger J, Langner J, Santos A N. Signal transduction via membrane peptidases. In: Ectopeptidases. New York: Kluwer Academic/Plenum Publishers, 2002: 141-170.
64. Turner A J, Isaac R E, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. BioEssays 2001: 23: 261-269.
65. Turner A J. Exploring the structure and function of zinc metallopeptidases: Old enzymes and new discoveries. Biochem Soc Trans 2003: 31: 723-727.
66. Beaumont A, Barbe B, Le Moual H et.al. Charge polarity reversal inverses the specificity of neutral endopeptidase-24.11. J Biol Chem 1992: 267: 2138-2141.
67. Beaumont A, Fournie-Zaluski M-C, Roques B P. Neutral endopeptidase-24.11: Structure, and design and clinical use of inhibitors. In: Hooper NM, ed. Zinc metalloproteases health and disease. London: Taylor & Francis, Publishers, 1996: 105-129.
68. Vijayaraghavan J, Scicli A G, Carretero O A, Slaughter C, Moomaw C, Hersh L B. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990: 265: 14150-14155.
69. Bradbury A F, Smyth D G, Snell C R. Prohormones of beta-melanotropin (beta-melanocyte-stimulating hormone, beta-MSH) and corticotropin (adrenocorticotropic hormone, ACTH): Structure and activation. Ciba Found Symp 1976: 41: 61-75.
70. Thorne B A, Viveros O H, Thomas G. Expression and processing of mouse proopiomelanocortin in bovine adrenal chromaffin cells. A model system to study tissue-specific prohormone processing. J Biol Chem 1991: 266: 13607-13615.
71. Thorne B A, Thomas G. An in vivo characterization of the cleavage site specificity of the insulin cell prohormone processing enzymes. J Biol Chem 1990: 265: 8436-8443.
72. Dickerson I M, Dixon J E, Mains R E. Biosynthesis and posttranslational processing of site-directed endoproteolytic cleavage mutants of pro-neuropeptide Y in mouse pituitary cells. J Biol Chem 1990: 265: 2462-2469.
73. Cromlish J A, Seidah N G, Chretien M. Selective cleavage of human ACTH, b-lipotropin, and the N-terminal glycopeptide at pairs of basic residues by IRCM-serine protease 1. Subcellular localization in small and large vesicles. J Biol Chem 1986: 261: 10859-10870.
74. Zhu X, Desiderio D M. Peptide quantification by tandem mass spectrometry. Mass Spectrom Rev 1997: 15: 213-240.
75. Desiderio D M. Quantitative analytical mass spectrometry of endogenous neuropeptides in human pituitaries. Life Sci 1992: 51: 169-176.
76. Desiderio D M, Yan L, Tseng J-L. Electrospray mass spectrometry analysis of opioid peptide-containing proteins. Regul Pept 1994: 54: 83-84.
77. Desiderio D M, Yan L, Fridland G, Tseng J-L. Mass spectrometric analysis of opioid peptide-containing proteins. Analgesia 1995: 1: 390-393.
78. Fridland G H, Desiderio D M. Detection of bovine pituitary opioid precursors during gel permeation using trypsin and cyanogen bromide treatment followed by radioimmunoassay. Anal Lett 1994: 27: 2117-2125.
79. Desiderio D M, Kusmierz J J, Zhu X et.al. Mass spectrometric analysis of opioid and tachykinin neuropeptides in non-secreting and ACTH-secreting human pituitary adenomas. Biol Mass Spectrom 1993: 22: 89-97.
80. Zhu X, Robertson J T, Sacks H S, Dohan F C Jr, Tseng J-L, Desiderio D M. Opioid and tachykinin neuropeptides in prolactin-secreting human pituitary adenomas. Peptides 1995: 16: 1097-1107.
81. Kusmierz J J, Dass C, Robertson J T, Desiderio D M. Mass spectrometric measurement of b-endorphin and methionine enkephalin in human pituitaries. Tumors and post-mortem controls. Int J Mass Spectrom Ion Process 1991: 111: 247-262.
82. Oliver R L, Davis J R E, White A. Characterisation of ACTH related peptides in ectopic Cushing's syndrome. Pituitary 2004: 6: 119-126.
83. Talbot J A, Kane J W, White A. Analytical and clinical aspects of adrenocorticotrophin determination. Ann Clin Biochem 2003: 40: 453-471.
84. Takahashi A, Yasuda A, Sullivan C V, Kawauchi H. Identification of proopiomelanocortin-related peptides in the rostral pars distalis of the pituitary in coelacanth: Evolutional implications. Gen Comp Endocrinol 2003: 130: 340-349.
85. Takahashi A, Amemiya Y, Yasuda A, Meguro H, Kawauchi H. Mass spectrometric detection of proopiomelanocortin (POMC)-related peptides following molecular cloning of POMC cDNA in bigeye tuna Thunnus obesus. Fish Sci 2002: 68: 1073-1080.
86. Vazquez-Martinez R M, Malagon M M, Van Strien F J C et.al. Analysis by mass spectrometry of POMC-derived peptides in amphibian melanotrope subpopulations. Life Sci 1999: 64: 923-930.
87. van Strien F J C, Jespersen S, van.der Greef J, Jenks B G, Roubos E W. Identification of POMC processing products in single melanotrope cells by matrix-assisted laser desorption/ionization mass spectrometry. FEBS Lett 1996: 379: 165-170.
88. van Strien F J C, Devreese B, Van Beeumen J, Roubos E W, Jenks B G. Biosynthesis and processing of the N-terminal part of proopiomelanocortin in Xenopus laevis: Characterization of g-MSH peptides. J Neuroendocrinol 1995: 7: 807-815.
89. Van Strien F J C, Jenks B G, Heerma W, Versluis C, Kawauchi H, Roubos E W. a, N -acetyl-b-endorphin(1-8) is the terminal product of processing of endorphins in the melanotroph cells of Xenopus laevis, as demonstrated by FAB tandem mass spectrometry. Biochem Biophys Res Commun 1993: 191: 262-268.
90. Slominski A, Szczesniewski A, Wortsman J. Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. J Clin Endocrinol Metab 2000: 85: 3582-3588.
91. Mazurkiewicz J E, Corliss D, Slominski A. Spatiotemporal expression, distribution, and processing of POMC and POMC-derived peptides in murine skin. J Histochem Cytochem 2000: 48: 905-914.
92. Aberdam E, Auberger P, Ortonne J P, Ballotti R. Neprilysin, a novel target for ultraviolet B regulation of melanogenesis via melanocortins. J Invest Dermatol 2000: 115: 381-387.
93. Siviter R J, Nachman R J, Dani M P, Keen J N, Shirras A D, Isaac R E. Peptidyl dipeptidases (Ance and Acer) of Drosophila melanogaster: Major differences in the substrate specificity of two homologs of human angiotensin I-converting enzyme. Peptides 2002: 23: 2025-2034.
94. Cushman D W, Gordon E M, Wang F L, Cheung H S, Tung R, Delaney N G. Purification and characterization of enkephalinase, angiotensin-converting enzyme, and a third peptidyl dipeptidase from rat brain. Life Sci 1983: 33: 25-28.
95. Bramucci M, Miano A, Quassinti L, Maccari E, Murri O, Amici D. Degradation of thymic humoral factor g2 by human plasma: Involvement of angiotensin converting enzyme. Regul Pept 2003: 111: 199-205.
96. Rieger K J, Saez-Servent N, Papet M P et al. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N -acetyl-seryl-aspartyl-lysyl-proline. Biochem J 1993: 296: 373-378.
97. Dubreuil P, Fulcrand P, Rodriguez M, Fulcrand H, Laur J, Martinez J. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogs with release of the amidated C-terminal dipeptide. Biochem J 1989: 262: 125-130.
98. Watanabe Y, Nakajima K, Shimamori Y, Fujimoto Y. Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med 1997: 61: 47-51.